Small Cell Lung Carcinoma: all 1,234 studies

Page 10 of 13. Open to participants first (350), then studies with results posted, then the rest; newest registration first within each.

• Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLCCompletedNCT03214003Not applicable
• Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung CancerWithdrawnNCT03166254Phase 1
• Molecular Profiling in Small Cell Lung CancerStatus unknownNCT03162705
• Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line ChemotherapyStatus unknownNCT03135977Phase 2
• The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung CancerStatus unknownNCT03129698Phase 2
• Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)TerminatedNCT03116971Phase 1
• Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR AmplificationTerminatedNCT03106155Phase 2
• A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung CancerStatus unknownNCT03100955Phase 3
• A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung CancerCompletedNCT03086239Phase 1
• SGI-110 Plus Durvalumab/Tremelimumab in SCLCCompletedNCT03085849Phase 1
• BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung CancerCompletedNCT03083691Phase 2
• A Study of APG-1252 in Patients With SCLC or Other Solid TumorsCompletedNCT03080311Phase 1
• Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized TrialStatus unknownNCT03077854Not applicable
• A Study Evaluating MM-310 in Patients With Solid TumorsStatus unknownNCT03076372Phase 1
• Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)CompletedNCT03059797Phase 2
• Immunotherapy as Second-line in Patient With Small Cell Lung CancerCompletedNCT03059667Phase 2
• PD-L1 and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced NSCLC PatientsStatus unknownNCT03029858
• Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A MutationsCompletedNCT03009682Phase 2
• FLT-PET/DW-MRI for Detection of Brain Metastases and Early Therapy Evaluation in Patients With Small Cell Lung CancerCompletedNCT02995902Not applicable
• FLT-PET for Early Detection of Relapse in Patients With Irradiated Lung CancerCompletedNCT02995889Not applicable
• Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)Status unknownNCT02995187Phase 2
• Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung CancerStatus unknownNCT02980809Phase 2
• Combining Radiosurgery and Nivolumab in the Treatment of Brain MetastasesCompletedNCT02978404Phase 2
• Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain TherapeuticStatus unknownNCT02972320Phase 2
• Study of BMS-986012 in Subjects With Small Cell Lung CanerCompletedNCT02949895Phase 1
• Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.CompletedNCT02945852Phase 2
• Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung CancerTerminatedNCT02937402Not applicable
• A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)CompletedNCT02913443Phase 1
• Memory and MRI Changes With Hippocampus Avoidance Prophylactic Cranial Irradiation(HA-PCI) for Small Cell Lung Cancer(SCLC)Status unknownNCT02906384Phase 2
• Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell CarcinomaCompletedNCT02881125Phase 1
• Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor ComplexWithdrawnNCT02876081Phase 2
• Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/CisplatinStatus unknownNCT02875457Phase 3
• A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung CancerCompletedNCT02874664Phase 1
• A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung CancerTerminatedNCT02819999Phase 1
• Trial of BMS-986012 in Combination With Platinum and EtoposideCompletedNCT02815592Phase 1
• Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung CancerStatus unknownNCT02772107Phase 2/3
• SBRT Compared With IMRT Concurrently With Chemotherapy in Treating Patients With LS-SCLCStatus unknownNCT02738723Phase 2
• SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013Status unknownNCT02738346Phase 3
• HS-WBRT for Prophylactic Cranial Irradiation in Limited Stage Small Cell Lung CancerStatus unknownNCT02736916Not applicable
• STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)TerminatedNCT02722369Phase 2
• Circulating Tumor DNA in Patients at High Risk for Lung CancerTerminatedNCT02715102
• Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 MutationTerminatedNCT02688907Phase 2
• DC Vaccine Combined With CIK Cells in Patients With SCLCStatus unknownNCT02688673Phase 1/2
• Comparable Study of Different Thoracic Radiotherapy Regimens for Extensive Stage Small Cell Lung CancerStatus unknownNCT02675088Not applicable
• A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor PatientsWithdrawnNCT02661100Phase 1/2
• Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsCompletedNCT02658214Phase 1
• LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic MalignanciesTerminatedNCT02649673Phase 1
• Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)Active, not recruitingNCT02628067Phase 2
• TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)TerminatedNCT02608411Phase 2
• Temozolomide in Preventing Brain Metastases in Small Cell Lung CancerStatus unknownNCT02605811Phase 2
• M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT02595931Phase 1
• Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer PatientsCompletedNCT02593019Phase 2
• Pembrolizumab in Untreated Extensive SCLCCompletedNCT02580994Phase 2
• Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOCStatus unknownNCT02577627
• Study of Split-course Chemoradiotherapy For Locally Advanced None-small Cell Lung CancerCompletedNCT02573506Phase 2
• Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney DysfunctionWithdrawnNCT02567396Phase 1
• Abscopal Effect for Metastatic Small Cell Lung CancerWithdrawnNCT02542137Phase 2
• AZD1775 Combined With Olaparib in Patients With Refractory Solid TumorsCompletedNCT02511795Phase 1
• SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine CarcinomaTerminatedNCT02500914Phase 1
• Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT MethylationTerminatedNCT02477813Phase 2
• Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior ChemotherapyStatus unknownNCT02446704Phase 1/2
• NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung CancerWithdrawnNCT02425072Phase 2
• Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL)CompletedNCT02397733Not applicable
• A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With CancerCompletedNCT02391480Phase 1
• Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in ChinaStatus unknownNCT02381808
• Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung CancerStatus unknownNCT02348450Phase 4
• Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy in Limited Small-cell Lung CancerStatus unknownNCT02337712Phase 2
• Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)TerminatedNCT02331251Phase 1/2
• PEI REGIMEN: A Therapeutic Option in Small Cell Lung Cancer? A Monoinstitutional Experience of 46 Consecutive CasesCompletedNCT02324296
• Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung CancerCompletedNCT02323737Phase 2
• Next-generation Sequencing of Small Cell Lung Cancer to Identify Actionable Targets for TreatmentTerminatedNCT02297087Not applicable
• Comprehensive Genomic Analysis in Tissue and Blood Samples From Young Patients With Lung CancerCompletedNCT02273336
• The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung CancerStatus unknownNCT02262897Phase 2
• Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin and EtoposideWithdrawnNCT02250404
• Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCompletedNCT02223052Phase 1
• Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLCCompletedNCT02200081Phase 2
• Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung CancerCompletedNCT02194049Phase 1
• Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC)Status unknownNCT02179528Phase 2
• Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer TreatmentStatus unknownNCT02171325Phase 2
• RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung CancerTerminatedNCT02161419Phase 2
• A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based ChemotherapyWithdrawnNCT02152059Phase 2
• A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic AlterationsTerminatedNCT02109016Phase 2
• Identification of Marker of Primary or Acquired Resistance to Anti Tumorous TreatmentStatus unknownNCT02105168Not applicable
• Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid TumorCompletedNCT02069158Phase 1
• Early Hippocampal Avoidance Prophylactic Cranial Irradiation in Patients With LD SCLCCompletedNCT02058056Not applicable
• Two Schedules of Hyperfractionated Thoracic Radiotherapy in Limited Disease Small Cell Lung CancerActive, not recruitingNCT02041845Not applicable
• Study of Gemcitabine Maintenance Treatment in Patients With Extensive SCLC PatientsStatus unknownNCT02039518Phase 2
• Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine CarcinomasWithdrawnNCT02030184Phase 1/2
• Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line ChemotherapyTerminatedNCT02011087Not applicable
• Impacts of Exercise on Prognostic Biomarkers in Lung Cancer PatientsCompletedNCT01999881Not applicable
• Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung CancerStatus unknownNCT01977235Phase 2
• Value of Physical Capacity Tests in Lung CancerCompletedNCT01943578
• CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung CancerCompletedNCT01931787Phase 1
• A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based ChemotherapyTerminatedNCT01904253Phase 2
• Temozolomide as Maintenance Therapy in Small Cell Lung CancerStatus unknownNCT01900951Phase 2
• Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung CancerTerminatedNCT01898156Phase 1/2
• Exercise in Advanced Stage Lung Cancer PatientsCompletedNCT01881906Not applicable
• A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung CancerStatus unknownNCT01872416Phase 2
• The Effect of Caphosol® on the Development of Esophagitis in (N)SCLC Patients Treated With Concurrent Chemo/RadiotherapyTerminatedNCT01809756Not applicable
• Pazopanib Maintenance for SCLCCompletedNCT01797874Phase 2

← Small Cell Lung Carcinoma overview